Stockscreener 앱 받기
7.85
1.63%
-0.13
시간 외 거래:
7.84
-0.010
-0.13%
전일 마감가:
$7.98
열려 있는:
$8.05
하루 거래량:
626.43K
Relative Volume:
0.82
시가총액:
$5.34B
수익:
$8.62B
순이익/손실:
$573.80M
주가수익비율:
11.10
EPS:
0.707
순현금흐름:
$680.05M
1주 성능:
-1.63%
1개월 성능:
-0.76%
6개월 성능:
-11.30%
1년 성능:
-6.10%
1일 변동 폭
$7.83
$8.07
1주일 범위
$7.83
$8.18
52주 변동 폭
$7.39
$11.14
그리폴스 Stock (GRFS) Company Profile
Compare GRFS vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.85 | 5.43B | 8.62B | 573.80M | 680.05M | 0.707 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
그리폴스 Stock (GRFS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 재개 | Morgan Stanley | Overweight |
| 2024-03-12 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-04-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2023-01-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-04-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-10-19 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2021-10-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-06-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 개시 | Deutsche Bank | Hold |
| 2021-03-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2020-10-01 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-06-09 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-06-09 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-03-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-06-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-02-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2018-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-06-01 | 개시 | Barclays | Overweight |
| 2017-10-31 | 개시 | Citigroup | Buy |
| 2017-06-30 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-04-06 | 개시 | BofA/Merrill | Buy |
| 2017-01-03 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-02-09 | 업그레이드 | Berenberg | Hold → Buy |
| 2016-01-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2015-11-20 | 다운그레이드 | Berenberg | Buy → Hold |
| 2015-04-28 | 다운그레이드 | Berenberg | Buy → Hold |
모두보기
그리폴스 주식(GRFS)의 최신 뉴스
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat - Investing.com
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
Grifols Q1 Earnings Call Highlights - Barchart
GRFS Stock Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com Canada
Grifols falls 6% after skipping 2026 revenue target; €7.52 bln sales - Investing.com
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
Judge Trims Most, But Not All, Of Grifols Suit Over Share Price - Law360
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar Australia
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
그리폴스 (GRFS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
1.31%
자본화:
|
볼륨(24시간):